NCT04712838View on ClinicalTrials.gov

Study on the Bioavailability of SHR0302 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

April 13, 2021

Study Completion Date

April 13, 2021

Conditions
Healthy Subjects
Interventions
DRUG

SHR0302

Group A subjects were given oral F1 、F2 and F3 version SHR0302

DRUG

SHR0302

Group B subjects were given oral F1 、F3 and F2 version SHR0302

DRUG

SHR0302

Group C subjects were given oral F2 、F1 and F3 version SHR0302

DRUG

SHR0302

Group D subjects were given oral F2 、F3 and F1 version SHR0302

DRUG

SHR0302

Group E subjects were given oral F3 、F1 and F2 version SHR0302

DRUG

SHR0302

Group F subjects were given oral F3 、F2 and F1 version SHR0302

Trial Locations (1)

100053

Xuanwu Hospital Beijing,Capital Medical University, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04712838 - Study on the Bioavailability of SHR0302 in Healthy Subjects | Biotech Hunter | Biotech Hunter